Daiichi Sankyo Company, Limited has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) for its influenza HA vaccine “Kaketsuken.” As per Agreement, sales activities of Kaketsuken will begin by Daiichi Sankyo from next season (2015-2016).
The Kaketsuken is an egg-based, inactivated vaccine used for prevention of seasonal influenza. Daiichi Sankyo is committed to the prevention of seasonal influenza through Kaketsuken, as well as to contributing to public health and preventive medicine in Japan through the provision of vaccines which fulfill unmet medical needs.
As well as, Daiichi Sankyo will continue to sell its current influenza HA vaccine, “Kitasatodaiichisankyo”.
Subscribe to PharmaTutor News Alerts by Email >>
